Clinical and Translational Allergy (Nov 2024)
GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management
- Torsten Zuberbier,
- Antonella Muraro,
- Ulugbek Nurmatov,
- Stefania Arasi,
- Katarina Stevanovic,
- Aikaterini Anagnostou,
- Roberta Bonaguro,
- Sharon Chinthrajah,
- Gideon Lack,
- Alessandro Fiocchi,
- Thuy‐My Le,
- Paul Turner,
- Montserrat Alvaro Lozano,
- Elizabeth Angier,
- Simona Barni,
- Phillippe Bégin,
- Barbara Ballmer‐Weber,
- Victoria Cardona,
- Carsten Bindslev‐Jensen,
- Antonella Cianferoni,
- Nicolette deJong,
- Debra deSilva,
- Antoine Deschildre,
- Audrey Dunn Galvin,
- Motohiro Ebisawa,
- David M. Fleischer,
- Jennifer Gerdts,
- Mattia Giovannini,
- Josefine Gradman,
- Susanne Halken,
- Syed Hasan Arshad,
- Ekaterina Khaleva,
- Susanne Lau,
- Richard Loh,
- Mika J. Mäkelä,
- Mary Jane Marchisotto,
- Laura Morandini,
- Charlotte G. Mortz,
- Caroline Nilsson,
- Anna Nowak‐Wegrzyn,
- Marcia Podestà,
- Lars K. Poulsen,
- Graham Roberts,
- Pablo Rodríguez del Río,
- Hugh A. Sampson,
- Angel Sánchez,
- Sabine Schnadt,
- Peter K. Smith,
- Hania Szajewska,
- Natasa Teovska Mitrevska,
- Alice Toniolo,
- Carina Venter,
- Amena Warner,
- Gary W. K. Wong,
- Robert Wood,
- Margitta Worm
Affiliations
- Torsten Zuberbier
- Institute of Allergology Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Antonella Muraro
- Food Allergy Referral Centre Department of Women and Children Health Padua University Hospital Padua Italy
- Ulugbek Nurmatov
- Division of Population Medicine School of Medicine Cardiff University Cardiff UK
- Stefania Arasi
- Allergy Unit Pediatric Hospital Bambino Gesù IRCCS Rome Italy
- Katarina Stevanovic
- Institute of Allergology Charité ‐ Universitätsmedizin Berlin Berlin Germany
- Aikaterini Anagnostou
- Department of Pediatrics Division of Allergy and Immunology Baylor College of Medicine Houston Texas USA
- Roberta Bonaguro
- Food Allergy Referral Centre Department of Women and Children Health Padua University Hospital Padua Italy
- Sharon Chinthrajah
- Sean N. Parker Center for Allergy and Asthma Research at Stanford University Stanford California USA
- Gideon Lack
- Paediatric Allergy King's College London London UK
- Alessandro Fiocchi
- Allergy Unit Pediatric Hospital Bambino Gesù IRCCS Rome Italy
- Thuy‐My Le
- Department of Dermatology/Allergology University Medical Center Utrecht Utrecht University Utrecht Netherlands
- Paul Turner
- Imperial College London London UK
- Montserrat Alvaro Lozano
- Pediatric Allergy and Clinical Immunology Department Hospital Sant Joan de Déu Barcelona Spain
- Elizabeth Angier
- Primary Care Population Science and Medical Education Faculty of Medicine University of Southampton Southampton UK
- Simona Barni
- Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
- Phillippe Bégin
- Section of Allergy and Clinical Immunology Department of Pediatrics Centre Hospitalier Universitaire Sainte‐Justine Montreal Quebec Canada
- Barbara Ballmer‐Weber
- Clinic for Dermatology and Allergology St. Gallen Switzerland
- Victoria Cardona
- Allergy Section Hospital Universitari Vall d'Hebron Barcelona Spain
- Carsten Bindslev‐Jensen
- Department of Dermatology and Allergy Centre Odense Research Centre for Anaphylaxis (ORCA) Odense University Hospital University of Southern Denmark Odense Denmark
- Antonella Cianferoni
- Allergy and Immunology Division Perelman School of Medicine The Children's Hospital of Philadelphia University of Pennsylvania Philadelphia Pennsylvania USA
- Nicolette deJong
- Internal Medicine Allergology & Clinical Immunology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands
- Debra deSilva
- The Evidence Centre London UK
- Antoine Deschildre
- University Lille INSERM Unit 1019 CNRS UMR 9017 CHU Lille Institut Pasteur de Lille Center for Infection and Immunity of Lille Lille France
- Audrey Dunn Galvin
- Allergy Research Group University College Cork Cork Ireland
- Motohiro Ebisawa
- Clinical Research Center for Allergy and Rheumatology NHO Sagamihara National Hospital Kanagawa Japan
- David M. Fleischer
- University of Colorado Denver School of Medicine Children's Hospital Colorado Aurora Colorado USA
- Jennifer Gerdts
- Food Allergy Canada Toronto Ontario Canada
- Mattia Giovannini
- Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
- Josefine Gradman
- Hans Christian Andersen Children's Hospital Odense University Hospital Odense Denmark
- Susanne Halken
- Hans Christian Andersen Children's Hospital Odense University Hospital Odense Denmark
- Syed Hasan Arshad
- Clinical and Experimental Sciences Faculty of Medicine University of Southampton Southampton UK
- Ekaterina Khaleva
- Faculty of Medicine University of Southampton Southampton UK
- Susanne Lau
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine Charité Universitätsmedizin Berlin Berlin Germany
- Richard Loh
- Medical School The University of Western Australia Perth Western Australia Australia
- Mika J. Mäkelä
- Skin and Allergy Hospital Helsinki University Central Hospital and University of Helsinki Helsinki Finland
- Mary Jane Marchisotto
- MJM Advisory New York New York USA
- Laura Morandini
- Food Allergy Referral Centre Department of Women and Children Health Padua University Hospital Padua Italy
- Charlotte G. Mortz
- Department of Dermatology and Allergy Centre Odense Research Centre for Anaphylaxis (ORCA) Odense University Hospital University of Southern Denmark Odense Denmark
- Caroline Nilsson
- Department of Clinical Science and Education Karolinska Institutet Stockholm Sweden
- Anna Nowak‐Wegrzyn
- Department of Pediatrics Hassenfeld Children's Hospital NYU Grossman School of Medicine New York City New York USA
- Marcia Podestà
- EFA ‐ European Federation of Allergy and Airways Diseases Patients' Associations Brussels Belgium
- Lars K. Poulsen
- Allergy Clinic Copenhagen University Hospital at Herlev‐Gentofte Copenhagen Denmark
- Graham Roberts
- Department of Paediatric Allergy and Respiratory Medicine University of Southampton Southampton UK
- Pablo Rodríguez del Río
- Hospital Infantil Universitario Niño Jesús Madrid Spain
- Hugh A. Sampson
- Division of Allergy and Immunology Department of Pediatrics Jaffe Food Allergy Institute Icahn School of Medicine at Mount Sinai New York New York USA
- Angel Sánchez
- AEPNAA Spanish Association of People with Food and Latex Allergy Madrid Spain
- Sabine Schnadt
- German Allergy and Asthma Association (DAAB) Mönchengladbach Germany
- Peter K. Smith
- Griffith University School of Medicine Gold Coast Queensland Australia
- Hania Szajewska
- Department of Paediatrics Medical University of Warsaw Warszawa Poland
- Natasa Teovska Mitrevska
- Dermatology Department Remedika General Hospital Skopje North Macedonia
- Alice Toniolo
- Food Allergy Referral Centre Department of Women and Children Health Padua University Hospital Padua Italy
- Carina Venter
- Food Allergy Canada Toronto Ontario Canada
- Amena Warner
- Allergy UK London UK
- Gary W. K. Wong
- Chinese University of Hong Kong Hong Kong Hong Kong
- Robert Wood
- Department of Pediatrics John Hopkins University School of Medicine Baltimore Maryland USA
- Margitta Worm
- Division of Allergy and Immunology Department of Dermatology, Allergy and Venerology Charité Universitätsmedizin Berlin Berlin Germany
- DOI
- https://doi.org/10.1002/clt2.70002
- Journal volume & issue
-
Vol. 14,
no. 11
pp. n/a – n/a
Abstract
Abstract Immunoglobulin E (IgE)‐mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti‐IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE‐mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE‐mediated food allergies, based on a systematic review and meta‐analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE‐mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.
Keywords
